Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C

Arima, Yuko; Kawabe, Naoto; Hashimoto, Senju; Harata, Masao; Nitta, Yoshifumi; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Kobayashi, Kyoko; Ichino, Naohiro; Osakabe, Keisuke; Nishikawa, Toru; Okumura, Akihiko; Ishikawa, Tetsuya; Yoshioka, Kentaro

doi:10.1111/j.1872-034x.2009.00618.x

Cited by 63 publications

(90 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation has already been made in earlier studies [35][36][37][38][39]. In our cohort, the range of changes in kPa was −4.2 to 41.8 kPa between baseline and FU24, 2.3 kPa to 29 kPa between baseline and FU96, and −2.6 to 18.7 between EOT and FU96.…”

Section: Discussionsupporting

confidence: 70%

“…In the previously mentioned Arima et al study and the Chekuri et al study, no further decrease in LS was observed after treatment in long-term follow-up-no change between in LS between 1 and 2 years of follow-up [35,37]. Conversely, in the Tada et al study, as mentioned above, an LS decrease was also observed 24 weeks after therapy completion [40].…”

Section: Discussionmentioning

confidence: 45%

“…In these studies, fibrosis declined by 29-82% depending on the time of observation (from 1.6 to 5.2 years). In the Arima et al study it was found that in 76% of patients who had F3-F4 fibrosis by liver biopsy prior to treatment, deduced fibrosis was reduced by 2 points in the fibrotic scale, and 46% of these patients had a reduction in fibrosis to F0-F1 (measured LS after treatment) [37]. It can be assumed that the LS changes not only illustrate the decline of the inflammatory process in the liver but also the regression of fibrosis and the LS measurement can visualize it in a faster way than the liver biopsy.…”

Section: Discussionmentioning

confidence: 99%

“…In the Arima et al study, patients treated with pegylated interferon (pegIFN) and RBV were followed, observing a mean LS drop by 5.3 (4.1-6.3) kPa in two-year follow-up [37]. However, in the Hezode et al study, the median decrease compared to baseline at the end of follow-up was 3.4 kPa, vs. 1.8 kPa in the patients who did not achieve an SVR [38].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Łucejko

Flisiak

2018

Applied Sciences

View full text Add to dashboard Cite

Abstract:To assess a combination of novel measures of therapeutic success in the treatment of chronic hepatitis C (CHC) infection, we evaluated liver stiffness (LS) with shear wave elastography and hepatitis C virus core antigen (HCVcAg) concentrations. We followed 34 patients during and after treatment with direct acting antivirals. All patients achieved a sustained virologic and serologic response and a significant increase of albumin levels. Decreases of alanine aminotransferase (ALT) activity and alpha-fetoprotein (AFP) level were observed during the treatment and follow-up period. A significant decrease in LS was observed between baseline, end of treatment (EOT), and at 24-and 96-week post-treatment follow-up. LS decline between EOT and 96-week follow-up (FU96) was observed in 79% of patients. Significant LS changes were seen in patients with advanced fibrosis, particularly in cirrhotics and in patients with ALT exceeding 100 IU/mL. There was a positive correlation between ALT activity and LS changes at the baseline versus FU96. A negative correlation was demonstrated between individual HCVcAg baseline concentrations and reduction of LS at the baseline versus FU96. In conclusion, we observed that LS significantly declined during and after antiviral treatment. It was accompanied by improvement in some liver function measures, and disappearance of both HCVcAg and HCV ribonucleic acid (HCV RNA).

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 45%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Łucejko

Flisiak

2018

Applied Sciences

View full text Add to dashboard Cite

show abstract

“…Preliminary study results indicate that the acoustic radiation force impulse (ARFI) elastography is a noninvasive method for measuring liver stiffness (LS) and can be used for the diagnosis of liver fibrosis and cirrhosis in chronic liver disease 17, 18, 19, 20, 21, 22, 23. However, the relationship between LS and its impact on the development of HCC remains unclear in chronic hepatitis C patients who achieved SVR following DAA therapy.…”

Section: Introductionmentioning

confidence: 99%

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals

et al. 2017

View full text Add to dashboard Cite

Background and AimPredictive factors for hepatocarcinogenesis following eradication of hepatitis C virus by direct‐acting antivirals (DAAs) are unknown. The aim of the study was to investigate the relationships between liver stiffness (LS) using acoustic radiation force impulse (ARFI) erastograghy and the development of hepatocellular carcinoma (HCC) in patients who achieved sustained virological response (SVR) treated with DAA.MethodsIn this prospective study, we enrolled 263 hepatitis C patients with SVR who underwent ARFI before DAA treatment. Thirty patients had previous HCC.ResultsThe median LS value according to ARFI measurements was 1.34 m/s (range: 0.67–4.35). During the follow‐up period (median: 18.1 months), development of HCC occurred in 19 patients (7.2%; HCC occurrence in 7 patients and HCC recurrence in 12 patients). By multivariate Cox regression analysis, HCC history (hazard ratio [HR]: 10.634; 95% confidence interval [CI]: 4.13–27.37; P = 0.001), older age (HR: 4.638; 95% CI: 1.63–13.61; P = 0.004) and higher total bilirubin levels (HR: 4.189; 95% CI: 1.66–10.60; P = 0.002) were independent predictors for the development of HCC, and higher LS value (≥1.73 m/s) at baseline was an independent predictor for HCC occurrence (HR: 8.350; 95% CI: 1.62–43.09; P = 0.011). The cumulative recurrence of HCC was statistically similar according to the degree of LS in patients who were previously treated for HCC.ConclusionThe LS value at baseline is useful for predicting HCC occurrence. Thus, even if SVR is achieved, patients with higher LS at baseline must be followed carefully for HCC occurrence.

show abstract

Assessing the Progression of Chronic HCV to Cirrhosis

Crespo

Martínez

Forns

2011

Chronic Hepatitis C Virus

View full text Add to dashboard Cite

Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C

Abstract: IFN treatment reduced LS in SVR patients and relapsers. Significant reduction of LS is associated with milder fibrosis stage, lower hyaluronic acid levels, longer IFN treatment, virological response of SVR or relapse and higher alanine aminotransferase levels.

Cited by 63 publications

References 48 publications

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Effect of HCV Core Antigen and RNA Clearance during Therapy with Direct Acting Antivirals on Hepatic Stiffness Measured with Shear Wave Elastography in Patients with Chronic Viral Hepatitis C

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals

Assessing the Progression of Chronic HCV to Cirrhosis

Contact Info

Product

Resources

About